⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3380 | 0.86 | — | — | |
| SCHEMBL1285757 | 0.83 | ESR1 (0.38) | — | |
| SCHEMBL127120 | 0.80 | — | — | |
| SCHEMBL16892560 | 0.77 | HTR1A (0.37) | — | |
| SCHEMBL16892539 | 0.74 | SIGMAR1 (0.47) | — | |
| SCHEMBL16892552 | 0.74 | ESR1 (0.36) | — | |
| SCHEMBL18741007 | 0.74 | CYP1A2 (0.33) | — | |
| SCHEMBL9579478 | 0.73 | — | — | |
| SCHEMBL1631743 | 0.70 | — | — | |
| SCHEMBL127484 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285775-B1 | Lactams and their use in the treatment of inter alia ocular hypertension or baldness | ALLERGAN INC (US) | 2017-03-22 | — | — | EP | claimed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | claimed |
| EP-2046714-B1 | Cyclopentane derivatives as antiglaucoma agents | ALLERGAN INC (US) | 2015-12-09 | — | — | EP | claimed |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. (US) | 2015-10-01 | — | — | US | claimed |
| EP-2043993-B1 | CYCLOPENTANE DERIVATIVES AS ANTIGLAUCOMA AGENTS | ALLERGAN INC (US) | 2015-07-01 | — | — | EP | claimed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | claimed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | claimed |
| EP-2069295-B1 | SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2013-12-18 | — | — | EP | claimed |
| US-8569349-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2013-10-29 | — | — | US | claimed |
| US-20130005767-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2013-01-03 | — | — | US | claimed |
| WO-2008008700-A2 | SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| WO-2008008701-A2 | SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-01-17 | — | — | US | claimed |
| WO-2008008718-A2 | CYCLOPENTANE DERIVATIVES AS ANTIGLAUCOMA AGENTS | ALLERGAN, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| WO-2007149829-A2 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2007-12-27 | — | — | WO | claimed |
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | ALLERGAN, INC. | 2007-12-20 | — | — | US | claimed |
| WO-2007130902-A2 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| US-20070259836-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. | 2007-11-08 | — | — | US | claimed |
| EP-1165557-B1 | ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS | NEUROGEN CORP (US) | 2004-09-29 | — | — | EP | claimed |
| US-6627624-B1 | Agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, | NEUROGEN CORPORATION | 2003-09-30 | — | — | US | claimed |